HHS Estimates Mylan Overcharged $1.27 Billion for the EpiPen Over a Decade

Drug Industry Daily
A A
The HHS inspector general’s office is estimating that taxpayers overpaid for the EpiPen by as much as $1.27 billion between 2006 and 2016.

To View This Article:

Login

Subscribe To Drug Industry Daily